bluebird bio, Inc. (BLUE)

Market Cap	98.06M
Revenue (ttm)	54.90M
Net Income (ttm)	-319.25M
Shares Out	193.91M
EPS (ttm)	-2.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,496,435
Open	0.497
Previous Close	0.497
Day's Range	0.481 - 0.509
52-Week Range	0.450 - 5.530
Beta	0.79
Analysts	Hold
Price Target	4.63 (+815.56%)
Earnings Date	Nov 5, 2024

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2013
• Employees: 375
• Stock Exchange: NASDAQ
• Ticker Symbol: BLUE
• Website: https://www.bluebirdbio.com

Financial Performance

In 2023, bluebird bio's revenue was $29.50 million, an increase of 720.04% compared to the previous year's $3.60 million. Losses were -$211.91 million, -8.00% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is $4.63, which is an increase of 815.56% from the latest price.

Price Target

$4.63

(815.56% upside)

Analyst Consensus: Hold